HARBIN, China, Oct. 14 /Xinhua-PRNewswire-FirstCall/ -- China Sky One
Medical, Inc. ("China Sky One Medical" or "the Company") (NASDAQ: CSKI), a
leading fully integrated pharmaceutical company producing over-the-counter
drugs in the People's Republic of China ("PRC"), announced today that it
started production at Peng Lai Jin Chuang Company ("Jin Chuang"), a
pharmaceutical company that it acquired, on October 14, 2008.

Jin Chuang, a subsidiary of China Sky One Medical, develops,
manufactures, and distributes pharmaceutical, medicinal and diagnostic
products in China. It owns rights to develop and market a portfolio of
twenty drugs approved by State Food and Drug Administration (SFDA) of the
PRC for the treatment of colds, cardiovascular disease, and depression. Jin
Chuang's products include Chinese health remedies such as Oyster Shell
Calcium Tablets for the treatment of osteoporosis, and Naftoipidil
Dispersible Tablets for the treatment of benign prostatic hyperplasia.
China Sky One Medical completed the acquisition of Jin Chuang on September
5, 2008, for approximately $7.1 million, consisting of cash and stock.
Production at Jin Chuang is moving smoothly and according to the Company's
schedule.

"We are pleased to have started production at Jin Chuang, which will
allow us to enhance our product line and increase our manufacturing
capabilities and profitability," said Mr. Yan-qing Liu, Chairman, CEO and
President of China Sky One Medical. "We expect Jin Chuang to contribute
$3-$5 million to sales in fiscal 2008, and approximately $0.95-$1.55
million in net profit for the year. We believe the acquisition will
increase our financial performance even further in 2009 as we scale up our
production. As a result of Jin Chuang's contribution, we are reaffirming
our previous full year 2008 guidance, which was provided on September 25,
2008."

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding
company. The Company engages in the manufacturing, marketing and
distribution of pharmaceutical, medicinal and diagnostic products. Through
its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and
Technology Company, Harbin First Bio- Engineering Company Limited, and
Heilongjiang Tianlong Pharmaceutical, Inc., the Company manufactures and
distributes over-the- counter pharmaceutical products, which make up its
major revenue source. For more information, visit
http://www.skyonemedical.com .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward-
looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995. These statements can be identified by the use of
forward- looking terminology such as "believe," "expect," "may," "will,"
"should," "project," "plan," "seek," "intend," or "anticipate" or the
negative thereof or comparable terminology. Such statements typically
involve risks and uncertainties and may include financial projections or
information regarding our future plans, objectives or performance. Actual
results could differ materially from the expectations reflected in such
forward-looking statements as a result of a variety of factors, including
the risks associated with the effect of changing economic conditions in The
People's Republic of China, variations in cash flow, reliance on
collaborative retail partners and on new product development, variations in
new product development, risks associated with rapid technological change,
and the potential of introduced or undetected flaws and defects in
products, and other risk factors detailed in reports filed with the
Securities and Exchange Commission from time to time.

(Date:12/8/2016)... CA (PRWEB) , ... December 08, 2016 , ... Lajollacooks4u, ... was a banner year for team building events, new program offerings and company expansion. ... it expanded earlier this year to include groups of over 30 people. Ever since, ...

(Date:12/8/2016)... Biotheranostics today announced that new data will ... Cancer Index (BCI) in identifying which patients with ... for disease recurrence and might benefit from extended ... advancing the understanding of the value of BCI ... inform decisions related to patient treatment. These data ...

(Date:11/21/2016)... Lithuania , Nov. 21, 2016 ... and object recognition technologies, today announced that the ... smart cards was submitted for the NIST ... successfully passed all the mandatory steps of the ... evaluation is a continuing test of fingerprint templates ...

(Date:11/15/2016)... Nov. 15, 2016 Synthetic Biologics, Inc. (NYSE ... focused on the gut microbiome, today announced the ... shares of its common stock and warrants to ... a price to the public of $1.00 per ... Biologics from the offering, excluding the proceeds, if ...